Qualigen Therapeutics (QLGN) announced that it received an expected deficiency notification letter from Nasdaq on April 24. The notice indicated that the company was not in compliance with Nasdaq Listing Rule 5250 as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue